Benzinga's Top #PreMarket Gainers

shares jumped 46.85% to $6.99 in pre-market trading ahead of January 5 conference call to discuss final results of Phase 2a trial of NurOwn in ALS.

shares jumped 6.54% to $17.10 in pre-market trading. Regulus Therapeutics shares have jumped 117.94% over the past 52 weeks, while the S&P 500 index has gained 12.39% in the same period.

shares rose 4.34% to $7.70 in pre-market trading after dropping 2.51% on Wednesday.

shares gained 3.63% to $14.55 in the pre-market trading session after tumbling 22.60% on Wednesday.

shares surged 3.17% to $59.50 in pre-market trading. Credit Suisse reiterated an Outperform rating on Kite Pharma and raised the price target from $34.00 to $71.00.